In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc. (NYSE:PFE) has agreed to pay up to $250 million. What Happened: The settlement, disclosed in a ...
GSK (NYSE:GSK) said it has started to appeal a recent court ruling in Delaware that allowed tens of thousands of lawsuits to ...
The decision of a Delaware judge on Friday to allow more than 75,000 Zantac lawsuits to go forward to jury trials has left ...
GSK Plc, Pfizer Inc. and other drugmakers must face trials in state court in Delaware after a judge found the evidence ...
Along with GSK and Pfizer, Sanofi and Boehringer Ingelheim GmbH have been sued by consumers. After the federal cases were ...
A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case ...
A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case ...
A woman who claimed in a lawsuit that GSK’s discontinued heartburn drug Zantac caused her breast cancer dropped her case ...
A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that ...
GSK’s shares fell sharply following a judge's decision to allow more than 70,000 lawsuits to proceed, alleging it’s Zantac ...
A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.
Last month, Shore Capital analysts estimated that up to $30bn (£24bn) for litigation was already priced into GSK’s shares. Pharma giant GSK is in hot water as it faces a barrage of lawsuits ...